'Market will see the value' in Imugene share price

Imugene shares might be in a slump, but the CEO is not giving up now.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

During the past 12 months, the S&P/ASX 200 Index (ASX: XJO) has dealt out an 8.1% return before dividends. Yet, the Imugene Limited (ASX: IMU) share price — an index constituent — has not seen anywhere near as positive of a performance.

Shares in the clinical-stage immuno-oncology company have painfully fallen 62% this past year. A staggering $760 million in market capitalisation has been stripped away, leaving Imugene at a value of $572 million today.

The discouraging move is hardly due to a lack of announcements. In total, 40 price-sensitive releases have been made by Imugene since this time last year. Still, the continuous flow of developments left the share price seemingly unphased.

So, why is the company's CEO adamant there will be better times ahead for shareholders?

Industry in a slump

On 6 July, Imugene CEO Leslie Chong issued a letter to shareholders. Chong noted no improvement in the broader biotechnology sector globally and within Australia in the letter.

A claim backed up by the weakness demonstrated across even the biggest biotech companies in the world. Take, for example, Pfizer Inc (NYSE: PFE) and AbbVie Inc (NYSE: ABBV) — two stalwarts of the industry — each carrying share price declines of more than 11% over the last year.

What is remarkable is that both of the abovementioned biotechs generate tens of billions of dollars each year in revenue. In addition, these are highly profitable businesses — not little drug developers still looking to land a moneymaker.

There are a few factors that could be at play here. However, the most impactful element for the Imugene share price is arguably the company's pre-product stage. According to the company's most recent presentation, all its programs are in phase II trials or earlier.

This creates an additional layer of risk for investors in an environment where 'risk-free' returns from bonds are much more attractive. As a result, capital is less inclined to flow toward the likes of Imugene until it provides improved signs of a return on investment (ROI).

However, the CEO highlighted her team's belief that "the market will see the value of our company and the opportunity in the share price."

What could drive the Imugene share price higher?

Being a clinical-stage biotech, the company's share price movement can depend highly on trial findings. Hence, any indication of positive outcomes from Imugene's various programs could bolster the share price.

In June, Imugene announced that the HER-Vaxx therapy had induced antibodies. The antibody response correlated with tumour reduction. The Imugene share price lifted 2.25% on the release day.

Furthermore, shareholders will undoubtedly want to see the company's other programs progressing from phase I to II. Fortunately, Imugene remains well funded with more than $150 million in cash at its disposal.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pfizer. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »